Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest
Cheaper versions of the “gamechanger” HIV prevention drug lenacapavir are to be made available in 120 low- and middle-income countries, manufacturer Gilead Sciences has announced.
However, campaigners said the deal “abandons” many countries with a high HIV burden, particularly in Latin America, and urged transparency over exact pricing.
About Author
More Stories
‘Godfather of AI’ shortens odds of the technology wiping out humanity over next 30 years
How owls helped me conquer my fear of the dark
‘All people could do was hope the nerds would fix it’: the global panic over the millennium bug, 25 years on